All Press Releases
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY
Malmö, 18 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice, establishing preclinical proof-of-concept. The hypothesis is…
PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)
Malmö, 13 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the appointment of Hampus Darrell as new CFO. Hampus Darrell is joining with an extensive professional accounting tenure, and he will provide financial and accounting expertise to PILA PHARMA, thus securing a continuous high standard of financial management and reporting. He graduated from Lund University,…
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
Malmö, 21 November 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The aim is to complete initial investigations on the effect of PILA PHARMA's lead molecule, XEN-D0501, on Abdominal Aorta…